tafinlar
novartis europharm limited - dabrafenib mesilate - melanooma - antineoplastiset aineet - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. adjuvanttihoitona melanomadabrafenib yhdessä trametinib on tarkoitettu adjuvanttihoitona aikuisille potilaille, joilla on vaiheen iii melanooma on braf v600-mutaatio, seuraava täydellinen resektio. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
mekinist
novartis europharm limited - trametinib - melanooma - antineoplastiset aineet - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ei-pienisoluinen keuhkosyöpä (nsclc)trametinib yhdessä dabrafenib on tarkoitettu aikuisille potilaille, joilla on pitkälle edennyt ei-pienisoluinen keuhkosyöpä, jossa on braf v600-mutaatio.
lopid 300 mg kapseli, kova
pfizer oy pfizer oy - gemfibrozilum - kapseli, kova - 300 mg - gemfibrotsiili
lopid 600 mg tabletti, kalvopäällysteinen
pfizer oy - gemfibrozil - tabletti, kalvopäällysteinen - 600 mg - gemfibrotsiili
pifeltro
merck sharp & dohme b.v. - doravirine - hiv-infektiot - antiviraalit systeemiseen käyttöön - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.
clindamycin navamedic 300 mg infuusioneste, liuos
navamedic asa - clindamycin phosphate - infuusioneste, liuos - 300 mg - klindamysiini
clindamycin navamedic 600 mg infuusioneste, liuos
navamedic asa - clindamycin phosphate - infuusioneste, liuos - 600 mg - klindamysiini
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiset aineet - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
sorafenib ratiopharm 200 mg tabletti, kalvopäällysteinen
teva b.v. - sorafenibum tosylatum - tabletti, kalvopäällysteinen - 200 mg - sorafenibi
sorafenib stada 200 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - sorafenib tosilate - tabletti, kalvopäällysteinen - 200 mg - sorafenibi